Determinants of teaching the educational discipline «Standardization of medicines» for future masters of pharmacy
DOI:
https://doi.org/10.57125/pedacademy.2024.06.29.20Keywords:
biosimilars, standardized methods, SPU, pharmaceutical analysisAbstract
Objective. The purpose of the article is to highlight the relevance of strengthening determinants during the teaching of the educational discipline «Standardization of Medicines» (StM) to students of higher education in higher education institutions of the pharmaceutical profile of Ukraine in accordance with the educational and professional program (EPP) «Pharmacy» of the second (master's) level of higher education with specialty 226 «Pharmacy, industrial pharmacy». It is important to modernize the educational and methodological complex and focus attention on standardized methods of pharmaceutical analysis of modern drugs, which are characterized by a non-standard composition, qualitatively different from analysis of generic drugs and require special approaches to quality analysis – drugs of biotechnological/biological origin (biosimilars).
Methods: analytical, systematic and logical.
Results. The modern determinants for the formation of an educational and methodological complex in the educational discipline of StM were considered, namely, methods of standardization of biotechnological/biological medicinal products; attention is focused on the importance of understanding the main differences between the pharmaceutical analysis of biosimilars and generic and original drugs of synthetic origin in order to successfully implement the professional competencies of future pharmacists.
Conclusions. With the active introduction of relevant determinants into the educational and methodological complex of the educational discipline of StM, the prospect of expansion and qualitative growth of the theoretical level, as well as the professional competences of future pharmacists, their ability to navigate modern world approaches to improved standardized methods of pharmaceutical analysis of biosimilars opens up, which directly affects increasing competitiveness of Ukrainian pharmacists.
